Skip to main content

Dyne Therapeutics, Inc.

corporate_fare Company Profile

Dyne Therapeutics, Inc.

DYN·NASDAQ·Life Sciences·CIK 0001818794

The company is a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. Its proprietary FORCE platform is designed to leverage the transferrin receptor 1, or TfR1, to deliver targeted therapeutics to muscle tissue and the central nervous system, or CNS. The FORCE platform utilizes an antigen-binding fragment antibody, or Fab, targeting TfR1 conjugated to a payload designed to target the genetic basis of the disease. The FORCE platform allows for the deployment of different classes of payloads, such as oligonucleotides and enzymes, with specific mechanisms of action. The company currently focuses on neuromuscular diseases with high unmet need, with etiologic targets and clear translational potential. Using its FORCE platform, the company is assembling a broad portfolio of product candidates, including those being developed for Duchenne muscular dystrophy, or DMD, myotonic dystrophy type 1, or DM1, facioscapulohumeral dystrophy, or FSHD, and Pompe disease. The company plans to expand its portfolio through development efforts focused on diseases involving the CNS, rare skeletal muscle diseases, and cardiac and metabolic muscle diseases. Product candidates have been identified for DMD (amenable to skipping exons 51, 53, 45, 44, and 55), DM1, FSHD, and Pompe programs, which are in varying stages of preclinical and clinical development. The product candidate zeleciment rostudirsen, or z-rostudirsen (also known as DYNE-251), is currently being evaluated in the DELIVER trial, a global Phase 1/2 clinical trial in patients with DMD amenable to exon 51 skipping. The company plans to submit a biologics license application, or BLA, to the U.S. Food and Drug Administration, or FDA, for U.S. Accelerated Approval of z-rostudirsen for DMD patients who have mutations amenable to exon 51 skipping in the second quarter of 2026 based on dystrophin as a surrogate endpoint.

Dyne Therapeutics, Inc. (NASDAQ:DYN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 44 items for DYN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for DYN spans 10-Q, 8-K, 4, 144.

Recent high-impact activity:

  • Dyne Q3 Loss Widens to $193.6M; Cash of $1.13B Funds Runway Into Q2 2028
  • Z-Basivarsen Delivers Durable One-Year Functional Gains in DM1, Separating From Natural History
  • Dyne's DYNE-101 Shows 12-Month Functional Gains in DM1; REC Topline Set for Q1 2027
  • Director Jason Rhodes Sells $65.2M in Dyne Stock via 10b5-1 Plan
  • Atlas Venture intends to sell $8.37M in Dyne stock, continuing recent distribution

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$446.21M
Diluted EPS
-$3.47
Op. Cash Flow
-$403.21M
Free Cash Flow
-$405.13M
Operating Income
-$468.18M
Cash & Equivalents
$893.37M
Total Debt
$148.92M
Debt / Equity
0.15×
Shares Outstanding
164.95M sh
Source: 10-K · filed 2026-03-02 · accession 0001193125-26-084178

Short Interest & Short Volume

10.81 days to cover

FINRA reported short interest of 24,376,615 shares in DYN as of the October 30, 2026 settlement, a 4.3% decrease from the prior period — about 10.8 days to cover at its recent average daily volume. On November 20, 2026, 33.1% of DYN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)24,376,615 shares as of October 30, 2026
Change vs prior period▼ 4.3%
Days to cover10.81 at avg daily volume of 2,255,177
Daily short volume (FINRA facilities)33.1% of 909,164 shares on November 20, 2026
5-day average short volume40.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for DYN, detected from its recent SEC filings · based on capital-structure filings through 2026-07-22.

1 recent capital raise

Upsized Offering Priced at Discount · Dilution Impact

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with D →
$15.5
52-week range · as of 2026-11-05 $14 – $27.3
Market cap
$2.9B
Volume
2.2M (0.9× avg)
3-mo avg 2.5M
Live data · 2026-11-22 03:02 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed DYN - Latest Insights

DYN
Nov 05, 2026, 7:25 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $18.63
Real-time Price: $15.50 info
Change: -$3.13 (-17%) info
Market Cap: $2.904B info
DYN
Sep 29, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.78
Real-time Price: $15.50 info
Change: -$0.280 (-2%) info
Market Cap: $2.904B info
DYN
Sep 29, 2026, 4:05 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $15.78
Real-time Price: $15.50 info
Change: -$0.280 (-2%) info
Market Cap: $2.904B info
DYN
Aug 17, 2026, 5:30 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $26.15
Real-time Price: $15.50 info
Change: -$10.65 (-41%) info
Market Cap: $2.904B info
DYN
Aug 14, 2026, 5:47 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $25.94
Real-time Price: $15.50 info
Change: -$10.44 (-40%) info
Market Cap: $2.904B info
DYN
Jul 29, 2026, 4:30 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $24.81
Real-time Price: $15.50 info
Change: -$9.31 (-38%) info
Market Cap: $2.904B info
DYN
Jul 29, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $24.81
Real-time Price: $15.50 info
Change: -$9.31 (-38%) info
Market Cap: $2.904B info
DYN
Jul 28, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $25.88
Real-time Price: $15.50 info
Change: -$10.38 (-40%) info
Market Cap: $2.904B info
DYN
Jul 22, 2026, 5:21 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $23.21
Real-time Price: $15.50 info
Change: -$7.71 (-33%) info
Market Cap: $2.904B info
DYN
Jul 22, 2026, 5:19 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $23.21
Real-time Price: $15.50 info
Change: -$7.71 (-33%) info
Market Cap: $2.904B info
DYN
Jul 21, 2026, 10:48 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $21.30
Real-time Price: $15.50 info
Change: -$5.80 (-27%) info
Market Cap: $2.904B info
DYN
Jul 21, 2026, 5:22 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $21.25
Real-time Price: $15.50 info
Change: -$5.75 (-27%) info
Market Cap: $2.904B info
DYN
Jul 21, 2026, 4:48 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $22.50
Real-time Price: $15.50 info
Change: -$7.00 (-31%) info
Market Cap: $2.904B info
DYN
Jul 20, 2026, 7:43 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $23.95
Real-time Price: $15.50 info
Change: -$8.45 (-35%) info
Market Cap: $2.904B info
DYN
Jul 20, 2026, 7:35 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $23.95
Real-time Price: $15.50 info
Change: -$8.45 (-35%) info
Market Cap: $2.904B info
DYN
Jul 07, 2026, 5:06 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $23.37
Real-time Price: $15.50 info
Change: -$7.87 (-34%) info
Market Cap: $2.904B info
DYN
Jul 07, 2026, 5:05 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $23.23
Real-time Price: $15.50 info
Change: -$7.73 (-33%) info
Market Cap: $2.904B info
DYN
Jun 29, 2026, 5:50 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $21.32
Real-time Price: $15.50 info
Change: -$5.82 (-27%) info
Market Cap: $2.904B info
DYN
Jun 29, 2026, 5:49 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $21.32
Real-time Price: $15.50 info
Change: -$5.82 (-27%) info
Market Cap: $2.904B info
DYN
Jun 26, 2026, 5:04 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $20.94
Real-time Price: $15.50 info
Change: -$5.44 (-26%) info
Market Cap: $2.904B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets